Expand all sections

Tiragolumab

Extended indication In combination with atezolizumab for first line treatment of locally advanced, unresectable Stage II
Therapeutic value No estimate possible yet
Registration phase Clinical trials

Product

Active substance Tiragolumab
Domain Oncology
Reason of inclusion New medicine (specialité)
Main indication Lung cancer
Extended indication In combination with atezolizumab for first line treatment of locally advanced, unresectable Stage III Non-small cell lung cancer in adults and elderly who have no progression during or following concurrent platinum-based chemoradiotherapy.
Manufacturer Roche
Mechanism of action PD-1 / PD-L1 inhibitor
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
ATMP No
Submission date January 2025
Expected Registration February 2026
Orphan drug Yes
Registration phase Clinical trials
Additional remarks NCT04513925

Therapeutic value

Therapeutic value No estimate possible yet

Expected patient volume per year

Patient volume

< 2,231

Market share is generally not included unless otherwise stated.
References 1. NKR;
Additional remarks In 2021 waren er 10.096 diagnoses NSCLC in Nederland. Dit betrof 1.727 patiënten in stadium I, 822 patiënten in stadium II, 2.231 patiënten in stadium III, 5.247 patiënten in stadium IV.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.